Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda and Ethypharm collaborate on NSAID
The companies believe that the combination of omeprazole (a proton pump inhibitor) and ketoprofen (NSAID) in one pill will avoid the gastrointestinal problems which are commonly associated with
The companies believe that the combination of omeprazole (a proton pump inhibitor) and ketoprofen (NSAID) in one pill will avoid the gastrointestinal problems which are commonly associated with
President and CEO Michael Friedman, vice president Howard Udell, and chief scientific officer Paul Goldenheim, will each make a payment and plead guilty to a single “strict liability”
Bristol-Myers Squibb will pay Isis a $15 million upfront licensing fee, and will provide Isis with at least $9 million in research funding over a period of three
The trials are now under way in collaboration with the Johns Hopkins Sidney Kimmel Cancer Center in patients with chronic myelogenous leukemia (CML). The studies include a new
The FDA has asked for additional clinical data in support of the efficacy claim for the drug made by Seattle-based Dendreon, which is seeking a clarification as to
The studies showed that women who took Pristiq experienced a reduction in both the number and severity of hot flashes. Additional analyses demonstrated that Pristiq reduced the number
The US and the whistleblowers, former Medicis sales representatives, alleged that Medicis urged doctors to use Loprox as a treatment for diaper rash. The use of Loprox, which
Lupin has already received FDA approvals for the capsule form and the lower strength suspension, and with this approval the company can launch the entire product range, Mumbai-based
However, Teva is currently in patent litigation with Eli Lilly over the drug in the US District Court for the Southern District of Indiana. A suit was brought
The compound, GMX1777, was licensed worldwide from LEO Pharma. The open-label, dose-escalation trial will enroll approximately 18-24 patients with refractory solid tumors and lymphomas at a single center.